Cargando…
Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM
BACKGROUND: Mechanisms of inflammation and protein accumulation are crucial in inclusion body myositis (IBM). Recent evidence demonstrated that intravenous immunoglobulin failed to suppress cell-stress mediators in IBM. Here we studied the molecular changes in skeletal muscle biopsies from patients...
Autores principales: | Schmidt, Karsten, Kleinschnitz, Konstanze, Rakocevic, Goran, Dalakas, Marinos C., Schmidt, Jens |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4833914/ https://www.ncbi.nlm.nih.gov/pubmed/27083892 http://dx.doi.org/10.1186/s12883-016-0568-5 |
Ejemplares similares
-
Interrelation of inflammation and APP in sIBM: IL-1β induces accumulation of β-amyloid in skeletal muscle
por: Schmidt, Jens, et al.
Publicado: (2008) -
Reply: Comment on alemtuzumab and inclusion body myositis
por: Dalakas, Marinos C., et al.
Publicado: (2010) -
Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis
por: Dalakas, Marinos C., et al.
Publicado: (2009) -
Quantitative clinical and autoimmune assessments in stiff person syndrome: evidence for a progressive disorder
por: Rakocevic, Goran, et al.
Publicado: (2019) -
Obinutuzumab, a potent anti–B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy
por: Rakocevic, Goran, et al.
Publicado: (2018)